Top Stories
Duke’s biobanks will give Network Bio access to patient samples linked to years of clinical records, helping train AI models for drug discovery and disease detection.
The combination of its marketed drug Kimmtrak and investigational T-cell engager brenetafusp posted an estimated two-year OS of 70% in metastatic uveal melanoma patients.
The study linked Repatha to a 20% lower risk of heart attacks in patients with atherosclerotic cardiovascular disease and prior statin use.
Eli Lilly's two GLP-1 offerings Zepbound (tirzepatide) and Foundayo (orforglipron) will be available via Hims & Hers' consumer platform.
The collaboration, focused on developing RNA editing candidates for cardiometabolic diseases, was on the rocks after being paused in Nov. last year.
Conference News
From tackling blood clots to managing blood pressure (BP), three separate trials presented at AHA 2026 – REDUCE, OCEANIC-STROKE and OPTIMAL-STROKE – offer new insights into improving outcomes after st...
Discontinuing statin therapy in older adults with at least two chronic conditions but no known cardiovascular disease was noninferior to continuation with respect to major cardiovascular events or dea...
American Heart Association Scientific Sessions 2026, Late-Breaking Science Abstract 27305Research Highlights:In a study of almost 1,900 adults, ages 70 years and older who had other chronic health con...
American Heart Association Scientific Sessions 2026, Late-Breaking Science Abstract 28064Research Highlights:Compared to standard treatment, using antihypertensive medications to lower systolic blood ...
American Heart Association Scientific Sessions 2026, Late-Breaking Science Abstract 27990Research Highlights:In a study of more than 3,000 adults in South Korea with heart or blood vessel disease, sta...
